ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials - Calle, R A; Amin, N B; Carvajal-Gonzalez, S (Nat Med, 2021)